ClinicalTrials.gg
Not yet recruitingNCT07859839GAZEBO-ILDUpdated Oct 8, 2026

Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD

A Phase 4 interventional study of Gabapentin and Benzonatate 200 mg in Interstitial Lung Disease, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Not yet recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Phase 4, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Lung Diseases, Interstitial with a site in India — 3 open to participants now, 6 under way, 2 of them phase 3. Lung Diseases, Interstitial · India.

Planned enrollment
6th of 14
177 · median 152
Started
2026
the only one that year
Phase 4
4 of 14
2 open now
Registered
14th of 14
by date
Lead sponsor
8 of 14
Post Graduate Institute of Medical Education and Research, Chandigarh

Among the 14 studies in Lung Diseases, Interstitial with a site in India, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 4, and was the 14th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

3 of the 14 studies in Lung Diseases, Interstitial with a site in India are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lung Diseases, Interstitial with a site in India, or all of them as a file.
02

Study summary

Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area. In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.

Read the detailed description

Cough in ILD Across ILD subtypes and geographic regions, dyspnoea on exertion and chronic cough are the most commonly reported symptoms. Chronic cough, defined by duration ≥ 8 weeks is the most common symptom in ILD. Cough is typically dry, persistent, and often disproportionate to radiological disease extent. In western studies, prevalence of among ILD subtypes was variable and the ILD subtype but is particularly prominent in IPF (83%) and HP (84%) compared to sarcoidosis where only 30-50% patients reports complaint of cough.

Impact of Cough on Quality of Life Chronic cough in ILD has a profound negative impact on health-related quality of life. Beyond physical discomfort, cough interferes with sleep, social interaction, communication, and emotional well-being. Studies using validated cough-specific instruments, such as the Leicester Cough Questionnaire, have demonstrated strong associations between cough severity and reduced quality-of-life scores. In patients with fibrotic ILD, cough-related quality-of-life impairment has also been linked to disease progression and poorer clinical outcomes, underscoring its relevance as a clinically meaningful symptom.

Current Recommendations for Management of Cough in ILD The management of cough in ILD remains challenging, as robust, ILD-specific evidence is limited. Current recommendations emphasize a systematic approach, beginning with optimization of treatment for the underlying ILD and identification of potentially reversible contributors such as gastro-oesophageal reflux, upper airway disease, infection, or medication-related cough. Pharmacological treatment recommended are thalidomide in IPF and gabapentin in refractory cough however the these are mostly by low quality evidence and expert consensus.

Gabapentin Gabapentin is a gabapentinoid originally developed as an antiepileptic agent and widely used for neuropathic pain. It binds to the α2δ subunit of voltage-gated calcium channels, leading to reduced excitatory neurotransmitter release and modulation of neuronal hyperexcitability. Chronic cough is increasingly understood as a manifestation of cough reflex hypersensitivity. Gabapentin is thought to suppress cough by attenuating central neural sensitization within the cough reflex pathway, thereby reducing abnormal afferent signalling and cough frequency. Randomized controlled trials in patients with chronic refractory cough have demonstrated that gabapentin significantly improves cough-specific quality of life and reduces cough severity compared with placebo. Although these studies were not ILD-specific, the findings have informed guideline recommendations and clinical practice, leading to cautious off-label use of gabapentin in patients with ILD-associated refractory cough.

Interstitial lung diseases (ILDs) are a group of heterogeneous disorders of the lung parenchyma characterized by inflammation and/or fibrosis resulting in dyspnoea and cough along with other symptoms and complications. In a study from 3089 patients of ILD from India, the crude prevalence of ILD in Northern Indians was 49.0-98.1, respectively per 100,000 population.

Chronic cough, defined by duration ≥ 8 weeks in a common symptom in ILD with a prevalence varying from 30% - 80% among various types. A 2018 study of 803 patients with ILD reported cough as the most common symptom with a prevalence of 86%. Currently, there is no FDA approved treatment for cough in ILD although various treatment strategies have been studied of which some are recommended by scientific societies which reflects lacunae in the evidence for treatment of cough in ILD.

It has been demonstrated that the sensitivity of the cough reflex is heightened in chronic cough. This has opened a new modality of neuromodulation-based treatment for chronic cough. Gabapentin is a gamma-aminobutyric acid (GABA) analogue that binds to the α2δ subunit of voltage-gated calcium channels of neurons and was initially introduced as an anti-seizure medication. A study by Ryan et al. showed significant relief in chronic cough with gabapentin, albeit this was a small study with a heterogeneous study population and not focused on ILD. A recent meta-analysis has also shown benefit with gabapentin in chronic cough treatment.

Benzonatate, initially used for cough suppression in 1958, represents another possible treatment option. It acts by anesthetizing the vagal stretch receptors in the lungs and pleura, thereby reducing the activation of the cough reflex at its origin. Benzonatate is a non-opioid antitussive structurally related to local anaesthetics. It exerts its antitussive effect primarily through peripheral mechanisms by anesthetizing stretch receptors in the respiratory tract and pleura, thereby dampening vagal afferent input to the cough center. Evidence supporting the use of benzonatate in chronic cough is limited. Small experimental studies suggest that it may reduce cough reflex sensitivity, particularly in acute cough settings. However, controlled clinical data demonstrating sustained benefit in chronic or ILD-related cough are sparse, and its role is generally confined to symptomatic relief rather than disease-modifying therapy. However, no clinical trial has shown its effectiveness in ILD.

Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area.

In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.

03

Conditions studied

  • Interstitial Lung Disease

Keywords

  • cough
  • ILD
  • pulmonary fibrosis
  • hypersensitivity pneumonitis
  • sarcoidosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Established diagnosis of ILD as defined by above
  2. Chronic cough (>= 8 weeks) with NRS ≥ 4/10
  3. On stable treatment for ≥ 8 weeks at screening

5. No to Gabapentin or Benzonatate Therapy

Exclusion criteria

Exclusion Criteria:

  1. Acute respiratory infection or ILD exacerbation leading to hospitalization within past 8 weeks of screening.
  2. Exposure to Gabapentin/Benzonatate within past 4 weeks
  3. Gastroesophageal reflux disease
  4. Upper airway cough syndrome
  5. Pregnant or Lactating women
  6. Decompensated Heart Failure ( (NYHA) Class III/IV)
  7. Renal Impairment ( \< 30ml/min/1.73m2)
  8. Chronic liver disease ( class B or C)
  9. Known to Gabapentin or Benzonatate
  10. Co-morbid bronchial asthma or (COPD)
  11. Long term oxygen therapy (LTOT)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
177 participants (estimated)

Study arms

  • Active comparator
    Gabapentin

    Participants will be treated with gabapentin at starting dose of 100 mg per dose, thrice daily and up titrated by 100 mg per dose every 3 days till 300 mg per dose, thrice daily or maximum tolerated dose. Standard Therapy including anti-fibrotic agent/s, immunosuppression therapy and symptomatic therapy for cough as per departmental treatment protocol (as needed dextromethorphan lozenges) shall be continued.

    Drug: Gabapentin · Other: Standard of care treatment for ILD

  • Active comparator
    Benzonatate

    Participants will be treated with Benzonatate at starting dose of 100 mg per dose thrice daily and up titrated to 200 mg per dose thrice daily after 3 days. Standard Therapy including anti-fibrotic agent/s, immunosuppression therapy and symptomatic therapy for cough as per departmental treatment protocol (as needed dextromethorphan lozenges) shall be continued.

    Drug: Benzonatate 200 mg · Other: Standard of care treatment for ILD

  • Other
    SOC

    Standard Therapy including immunosuppressive and/or anti-fibrotic agent/s and symptomatic therapy for cough (as needed dextromethorphan lozenges)

    Other: Standard of care treatment for ILD

Interventions

  • Gabapentin at starting dose of 100 mg per dose, thrice daily and up titrated by 100 mg per dose every 3 days till 300 mg per dose, thrice daily or maximum tolerated dose

  • DrugBenzonatateStudies of BenzonatateBenzonatate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Benzonatate at starting dose of 100 mg per dose thrice daily and up titrated to 200 mg per dose thrice daily after 3 days

  • OtherStandard of care treatment for ILD

    Standard Therapy including immunosuppressive and/or anti-fibrotic agent/s and symptomatic therapy for cough (as needed dextromethorphan lozenges)

06

What researchers measure

Primary outcomes

  1. Cough intensity in Gabapentin group

    Difference in change in numerical rating scale (NRS 0-10) for cough from baseline to 8 weeks between the gabapentin and the standard of care groups.The cough numerical rating scale (NRS) is a simple, self-reported tool used to measure chronic cough severity, frequency, or the urge to cough on an 11-point scale from 0 to 10. 0: No cough (or no symptoms at all). 10: The most severe or worst possible cough imaginable. Higher scores: Indicate worse symptoms and greater severity.

    Time frame: 8 weeks

  2. Cough intensity in benzonatate arm

    Difference in change in numerical rating scale (NRS 0-10) for cough from baseline to 8 weeks between the benzonatate and the standard of care groups. The cough numerical rating scale (NRS) is a simple, self-reported tool used to measure chronic cough severity, frequency, or the urge to cough on an 11-point scale from 0 to 10. 0: No cough (or no symptoms at all). 10: The most severe or worst possible cough imaginable. Higher scores: Indicate worse symptoms and greater severity.

    Time frame: 8 weeks

Secondary outcomes

  1. Cough VAS in gabapentin group

    Difference in the change in the visual analog scale (VAS) score for cough at 8 weeks between gabapentin and standard of care groups. The cough severity visual analog scale (VAS) is a 100-millimeter linear line that lets patients rate their cough intensity from \[0 mm ("no cough")\] to \[100 mm ("worst imaginable cough")\]. Format: A straight horizontal or vertical line measuring exactly 100 mm long. Anchors: The bottom or left end is marked 0 ("No cough"), and the top or right end is marked 100 ("Worst cough"). Scoring: The patient makes a mark on the line matching their symptom severity, and the distance in millimeters from zero to the mark is measured. Higher scores indicate worse cough.

    Time frame: 8 weeks

  2. Cough VAS in benzonatate arm

    Difference in the change in the visual analog scale (VAS) score for cough at 8 weeks between benzonatate and standard of care groups. The cough severity visual analog scale (VAS) is a 100-millimeter linear line that lets patients rate their cough intensity from \[0 mm ("no cough")\] to \[100 mm ("worst imaginable cough")\]. Format: A straight horizontal or vertical line measuring exactly 100 mm long. Anchors: The bottom or left end is marked 0 ("No cough"), and the top or right end is marked 100 ("Worst cough"). Scoring: The patient makes a mark on the line matching their symptom severity, and the distance in millimeters from zero to the mark is measured. Higher scores indicate worse cough.

    Time frame: 8 weeks

  3. Leicester Cough questionnaire (LCQ) score in gabapentin arm

    Difference in the change in leicester cough questionnaire (LCQ) total score at 8 weeks between gabapentin and standard of care groups.The Leicester Cough Questionnaire (LCQ) is a brief, 19-item self-administered tool used to measure the impact of a chronic cough on an adult's quality of life over the previous two weeks. The questionnaire splits the 19 items into three specific areas of health: Physical (8 items): Evaluates chest or stomach pains, phlegm, hoarseness, sleep disruption, energy levels, and coughing bouts. Psychological (7 items): Measures tiredness, feelings of control, embarrassment, anxiety, frustration, and worry about serious illness. Social (4 items): Assesses interference with jobs, daily enjoyment, conversations, and relationships. Scoring and Interpretation: Scale: Each item is rated on a 7-point Likert scale (ranging from 1 to 7). Total Score Range: From 3 to 21. Higher scores indicate a better quality of life and less impact from the cough

    Time frame: 8 weeks

  4. Leicester Cough questionnaire score in the benzonatate arm

    Difference in the change in leicester cough questionnaire (LCQ) total score at 8 weeks between benzonatate and standard of care groups.The Leicester Cough Questionnaire (LCQ) is a brief, 19-item self-administered tool used to measure the impact of a chronic cough on an adult's quality of life over the previous two weeks. The questionnaire splits the 19 items into three specific areas of health: Physical (8 items): Evaluates chest or stomach pains, phlegm, hoarseness, sleep disruption, energy levels, and coughing bouts. Psychological (7 items): Measures tiredness, feelings of control, embarrassment, anxiety, frustration, and worry about serious illness. Social (4 items): Assesses interference with jobs, daily enjoyment, conversations, and relationships. Scoring and Interpretation: Scale: Each item is rated on a 7-point Likert scale (ranging from 1 to 7). Total Score Range: From 3 to 21. Higher scores indicate a better quality of life and less impact from the cough

    Time frame: 8 weeks

  5. ILD-related quality of life assess using the King's brief interstitial lung disease score in gabapantin arm

    Difference in the change in king's brief interstitial lung disease quality of life groups questionnaire (K-BILD) at 8 weeks between gabapentin and standard of care. The King's Brief Interstitial Lung Disease (K-BILD) questionnaire is a validated, patient-reported outcome tool to measure the health-related quality of life (HRQoL) in adults living with interstitial lung disease (ILD). It consists of 15 items scored on a 7-point Likert scale. It assesses the patient's respiratory health and well-being over the preceding 2 weeks. Scoring: The total score and separate domain scores range from 0 to 100, where 100 represents the best possible health status and 0 represents the worst.

    Time frame: 8 weeks

  6. ILD-related quality of life assessed using the king's brief interstitial lung disease quality of life groups questionnaire (K-BILD)

    Difference in the change in king's brief interstitial lung disease quality of life groups questionnaire (K-BILD) at 8 weeks between benzonatate and standard of care. The King's Brief Interstitial Lung Disease (K-BILD) questionnaire is a validated, patient-reported outcome tool to measure the health-related quality of life (HRQoL) in adults living with interstitial lung disease (ILD). It consists of 15 items scored on a 7-point Likert scale. It assesses the patient's respiratory health and well-being over the preceding 2 weeks. Scoring: The total score and separate domain scores range from 0 to 100, where 100 represents the best possible health status and 0 represents the worst.

    Time frame: 8 weeks

  7. Treatment-emergent adverse effects

    difference in the incidence of treatment-emergent adverse effects between the study groups. The averse effects will include drowsiness, dizziness, throat numbness, nausea, constipation, and any other side effects reported by the study subjects

    Time frame: 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified data related to study's primary and secondary outcomes

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication of the primary manuscript of the study

Access criteria: Non-commercial/academic entities who make a reasonable request

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Oct 7, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 2 updates
  1. Oct 8, 2026
    Minor edits only
    + 2 other changes: verification date and description
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859839
Responsible party
Sahajal Dhooria (Additional Professor of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Oct 6, 2026
Start date
Oct 7, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Sahajal Dhooria, MD, DM
Contact
sahajal@gmail.com
+91 172 2756822
Gaurav Sarnaik, MD
Contact
ghsarnaik@gmail.com
Sahajal Dhooria, MD, DM
principal investigator · Postgraduate Institute of Medical Education and Research, Chandigarh, India

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gabapentin · Benzonatate

Start the discussion